Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Telix Pharmaceuticals, with four buy ratings, one strong-buy rating and two holds. The average 12-month price target is $20.40, well above the reported $11.45 share price.
• Recent analyst views were mixed: RBC downgraded the stock to “sector perform,” while HC Wainwright and Citigroup maintained buy ratings and Wedbush reaffirmed “outperform,” with targets ranging from $20 to $22.
• Institutional interest increased as several funds initiated or expanded positions, while Telix shares were reported up 5.5%. The stock is trading between a 52-week range of $6.28 and $12.48.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.40.

A number of research analysts have commented on the company. Royal Bank Of Canada lowered Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday. Wedbush reaffirmed an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Weiss Ratings raised Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, August 21st. Finally, Citigroup reiterated a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TLX. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the 3rd quarter worth approximately $1,883,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $1,731,000. Portland Investment Counsel Inc. lifted its holdings in Telix Pharmaceuticals by 108.0% in the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company's stock valued at $2,063,000 after buying an additional 138,200 shares during the period. Lazard Asset Management LLC lifted its holdings in Telix Pharmaceuticals by 118.6% in the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company's stock valued at $1,876,000 after buying an additional 135,893 shares during the period. Finally, Private Advisor Group LLC boosted its stake in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after acquiring an additional 128,070 shares during the last quarter.

Telix Pharmaceuticals Trading Up 5.5%

Shares of Telix Pharmaceuticals stock opened at $11.45 on Thursday. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The firm has a 50 day simple moving average of $11.17 and a 200 day simple moving average of $9.91. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $12.48.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source